

Identification of Lead Candidate for PD-L1/** Bispecific Antibody

GI Innovation Inc.



ONCOLOGY	Lead
Product Type	BsAb (Bispecific Antibody)
Indication	Solid tumors (ICI-refractory/resistant tumors with elevated macrophage levels in the tumor microenvironment)
Target	Programmed Death-Ligand 1 [PD-L1] and ** [**]
MoA (Mechanism of Action)	<ul style="list-style-type: none"> • Anti-PD-L1: Restoration of anti-tumor immune cell (CD8⁺ T cell/NK cell) activity via PD-1/PD-L1 signaling inhibition and increased contact between PD-L1-positive tumor cells and macrophages through tumor cell targeting. • Anti-**: Enhancement of anti-tumor activity in macrophages and boosting anti-tumor immune activity of CD8⁺ T cells and NK cells via ** signaling inhibition.
Competitiveness	<ul style="list-style-type: none"> • PD-L1/** BsAb restores the activity of anti-tumor immune cells through PD-1/PD-L1 signaling inhibition and enhances the tumor-suppressing ability of macrophages through ** signaling inhibition. • PD-L1/** BsAb plays a role as a myeloid engager that targets PD-L1-positive tumor cells and increases macrophage contact with tumor cells, thereby enhancing drug efficacy. • PD-L1/** BsAb is a first-in-class drug for targeting both PD-L1 and **. • PD-L1/** BsAb is expected to show synergistic effects when co-administered with existing standard therapies or blockbuster immune checkpoint inhibitors.
Development Stage	Lead
Route of Administration	Intravenous (i.v) administration